ArticleBrain tumor research and treatment2017
Ependymomas: Prognostic Factors and Outcome Analysis in a Retrospective Series of 33 Patients.
Article in Brain tumor research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 21 citations in OpenAlex.
- Preoperative MR - based model for predicting prognosis in patients with intracranial extraventricular ependymoma.European journal of radiology open · 2025Article
- Epidemiological characteristics of myxopapillary ependymoma and factors affecting overall survival: a SEER-based analysis.Translational cancer research · 2024Article
- Radiotherapy dosing in intracranial ependymoma using the national cancer database.Journal of neuro-oncology · 2024Article
- Risk factors for early intraventricular hemorrhagic complications following lateral ventricular tumor surgery.Neurosurgical review · 2024Article
- Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.BMC cancer · 2020Observational
- Subcutaneous sacrococcygeal myxopapillary ependymoma misdiagnosed as pilonidal disease.BMJ case reports · 2020Article
- Treatment Decisions of World Health Organization Grade II and III Ependymomas in Molecular Era.Journal of Korean Neurosurgical Society · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to evaluate the prognostic factors and outcomes in patients with ependymoma to management plans.
methodsBetween 1997 and 2013, 33 patients with 25 ependymomas (WHO grade II) and eight anaplastic ependymomas (WHO grade III) were pathologically diagnosed. Six were pediatric patients (mean age, 6.15 years; range, 1.3-11 years), while 27 were adults (mean age, 47.5 years; range, 19-70 years). Of those, there were 12 adult patients with totally resected ependymomas without anaplastic pathology and adjuvant treatment. Prognostic factors were assessed in ependymoma patients. Prognostic factors were studied using Kaplan-Meier estimates in subgroups.
resultsFor six pediatric patients, the progression-free survival (PFS) was 43.7±13.5 months, and the overall survival (OS) was 58.1±13.7 months. For 27 adult patients, the PFS was 125.6±14.3 months, and the OS was 151.2±12.5 months. Age demonstrated a statistically significant effect on PFS (
conclusionAdult patients with ependymomas were found to have better survival rates compared to pediatric patients. We suggest that totally resected adult ependymomas without anaplastic pathology could be observed without any adjuvant treatment, regardless of the tumor location.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.